You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on breast cancer.
Researchers found that cancer patients with BRCA2 mutations respond particularly well to checkpoint inhibitors compared to those with BRCA1 mutations.
The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.
The firm is still designing the study, which will explore the ability of GP2 to prevent recurrence in HER2-postive breast cancer after surgery.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.
Trodelvy's clinical development in China, led by Everest Medicines, follows the agent's US accelerated approval in April for triple-negative breast cancer.
The Phase III trial will compare Enhertu against Kadcyla as an adjuvant treatment for early-stage HER2-positive breast cancer patients.
FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The Broad Institute's CRISPR paralog screening platform will inform Ideaya's synthetic lethality-based target and biomarker discoveries.
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.